ArticleAnalytical and bioanalytical chemistry2026
Integrated dual-MS platform lipidomics and transcriptomics approach to investigate the lipid-inflammatory crosstalk mechanism of Gushudan in preventing postmenopausal osteoporosis rats.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lipid metabolism imbalance and inflammation are important mechanisms driving osteoporosis. Gushudan (GSD) has the effect of tonifying the kidney and strengthening bones. However, the preventive mechanism of GSD against postmenopausal osteoporosis (PMOP) by modulating lipid metabolism remains to be further elucidated. A multi-omics strategy integrating lipidomics, transcriptomics, network pharmacology, and molecular docking was developed to investigate the potential mechanistic targets and pharmacodynamic material basis of GSD in preventing PMOP. Firstly, lipidomics analysis employing the dual-MS platform of UHPLC-Q-Orbitrap HRMS and UHPLC-MS/MS demonstrated that GSD improved the disorder of the lipid-inflammatory crosstalk mechanism involving glycerophospholipids and arachidonic acid in PMOP rats. Secondly, the combined analysis of lipidomics and network pharmacology predicted that Pla2g2a might be a potential mechanistic target linking lipid metabolism disorder to PMOP. Furthermore, high-throughput RNA sequencing transcriptomics was conducted to reveal that GSD significantly regulated 49 differentially expressed genes in PMOP rats, with the reversed genes (represented by Pla2g2a) markedly enriched in the arachidonic acid metabolism pathway. Finally, molecular docking was used to screen four active ingredients: przewaquinone A, naringenin, salvianolic acid D, and tricin, which were found to target Pla2g2a. In conclusion, this work achieved multi-dimensional cross-analysis by integrating multiple approaches, suggesting that GSD might ameliorate the lipid-inflammatory crosstalk disorder in PMOP rats by downregulating Pla2g2a expression, thereby restoring bone homeostasis. These findings provide new research clues and a potential target basis for the mechanistic investigation of PMOP.
Indexed as
Identifiers
42101489What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.